CHARLOTTESVILLE, Va. - Adial Pharmaceuticals (NASDAQ:ADIL), Inc. (NASDAQ:ADIL; ADILW), a biopharmaceutical company engaged in developing treatments for addiction and related disorders, recently announced the issuance of a U.S. patent for its investigational drug AD04, aimed at treating opioid use disorder (OUD).
The patent, number 11,905,562, granted on February 20, 2024, covers AD04's method targeting the serotonin transporter gene.
Cary Claiborne, CEO of Adial Pharmaceuticals, stated that this patent adds to the company's intellectual property portfolio and highlights the unique aspects of AD04, particularly its targeting mechanism. Claiborne expressed the company's belief in AD04's potential for treating not only OUD but also other drug dependencies beyond its initial focus on alcohol use disorder (AUD).
AD04 is a genetically targeted serotonin-3 receptor antagonist currently under investigation. Following promising results from the ONWARD™ pivotal Phase 3 clinical trial for AUD treatment in patients with certain genetic profiles, AD04 is also being considered for the treatment of other addictive behaviors, including gambling and obesity.
While the company is optimistic about AD04's future applications and commercialization for AUD treatment, these statements are forward-looking and involve numerous assumptions and risks. The outcomes are subject to change based on various known and unknown factors.
The development of AD04 is part of Adial Pharmaceuticals' broader commitment to addressing addiction and related disorders through targeted therapies. The company's approach includes the use of proprietary diagnostic tests to identify suitable candidates for their treatments.
This news is based on a press release statement from Adial Pharmaceuticals, Inc. and reflects the company's current views and intentions regarding the future of AD04. The statements made are forward-looking and should be considered in the context of the risks and uncertainties inherent in the development and regulatory approval process of new drug products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.